Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration ...

CTx-1301 is a novel proprietary formulation of dexmethylphenidate, a stimulant that increases norepinephrine and dopamine activity in the brain.

The ADHD trait group was identified based on self-reported symptoms using three widely used tools: the Barkley Adult ADHD Rating Scale, the Adult ADHD Self-Report Screening Scale for DSM-5, and the ...

Adult attention deficit hyperactivity disorder (ADHD) is a diagnosis that is primarily clinical, based upon the DSM-IV criteria. This set of criteria requires that current symptoms suggest this ...

May 11, 2004 (New York) — Editor's Note: Attention deficit hyperactivity disorder (ADHD) in adults is only beginning to be understood and delineated by clinicians and researchers. Dr. Martin Korn ...

Targacept announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). This trial is a double-blind, placebo ...

Scientists have found that ADHD (Attention-Deficit/Hyperactivity Disorder) in women is diagnosed approximately five years ...

BOSTON — October 25, 2007 –– Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a study which demonstrated that adults with ...

Targacept, Inc (NASDAQ: TRGT) today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder (ADHD). In the ...

Attention deficit hyperactivity disorder (ADHD) is a disorder of childhood but remains active into adulthood in about 10-60% of patients. The symptomatology does not differ from childhood to adulthood ...